Aurobindo Pharma recalls two lots of Lisinopril tablets: Report

07 Jun 2013 Evaluate

Aurobindo Pharma has reported that Aurobindo Pharma USA, the company’s subsidiary has voluntarily recalled two lots of the anti-hypertensive Lisinopril tablets, 30 mg, from the US market due to a labeling error.

The company initiated the recall on April 9 as the label on the bottles of the drug mentioned the incorrect strength. The recall has been classified under Class-III, which the USFDA defines as products that are unlikely to cause any adverse health reaction but violate FDA labeling or manufacturing laws.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1175.35 -10.15 (-0.86%)
16-Dec-2025 10:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1784.50
Dr. Reddys Lab 1276.05
Cipla 1501.55
Zydus Lifesciences 921.95
Lupin 2084.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×